Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 20,623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Terminated Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

NCT04895410
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lemzoparlimab, Dexamethasone, Carfilzomib, Pomalidomide, Daratumumab
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
12
States / cities
Miami, Florida • Tampa, Florida • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Sefaxersen (RO7434656), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Withdrawn Phase 1 Interventional

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

NCT01969682
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABT-199, Rifampin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Nov 1, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT01862224
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JNJ-38518168, Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Nov 1, 2026, 1:29 AM EDT
Recruiting Phase 1 Interventional

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

NCT07105059
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Mezigdomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Completed No phase listed Observational

CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis

NCT05671055
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Custom study version of icompanion app
Other
Lead sponsor
icometrix
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Aurora, Colorado • Fort Collins, Colorado • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 3 Interventional

A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders

NCT00266578
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Marc Rothenberg
Other
Eligibility
3 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Nov 1, 2026, 1:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

NCT00001885
View directory record Official record
Conditions
Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 1:29 AM EDT
Not listed Phase 1 Interventional

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

NCT03588715
View directory record Official record
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Nov 1, 2026, 1:29 AM EDT
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

NCT03524235
View directory record Official record
Conditions
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Fludarabine, Rituximab
Radiation · Procedure · Biological + 1 more
Lead sponsor
Noah Merin
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional Results available

CSP #512 - Options in Management With Anti-Retrovirals

NCT00050089
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP, Standard ART vs Mega ART
Other · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
29
States / cities
Phoenix, Arizona • Long Beach, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

NCT01885897
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma, Myeloma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML)
Interventions
ALT-803
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Full Day and Night Closed-Loop With DiAs Platform

NCT02147860
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Nov 1, 2026, 1:29 AM EDT
Not listed No phase listed Observational

Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)

NCT05692713
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
St Louis, Missouri • Omaha, Nebraska • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Nov 1, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

NCT00614458
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir; valproic acid
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2011 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

NCT00002213
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Berkeley, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 1:29 AM EDT
Terminated Phase 1 Interventional

Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema

NCT00517582
View directory record Official record
Conditions
Angioneurotic Edema
Interventions
HOE-140, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Nov 1, 2026, 1:29 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

OTIS Cimzia Pregnancy Registry

NCT01797224
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
925 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Nov 1, 2026, 1:29 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 1, 2026, 1:29 AM EDT
Terminated Phase 1 Interventional Results available

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

NCT03286114
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions
Pembrolizumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Nov 1, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Healthier Living Canada

NCT01047514
View directory record Official record
Conditions
Asthma, Chronic Disease
Interventions
Chronic Disease Self-Management Online Workshop
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Nov 1, 2026, 1:29 AM EDT